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Monday, February 17, 2014 263acombinatorial chemistry library and first principles based alchemical calcula-
tions for accurate free energy estimates appears to be a powerful approach
for ligand optimization.
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Mitogen-activated protein kinases-interacting kinases 1 and 2 (MNK1 and
MNK2) are Ser/Thr kinases belongs to the group of Ca2þ/calmodulin-depen-
dent kinases (CaMK) that phosphorylate Eukaryotic initiation factor 4E
(eIF4E) [Luc Furic.,et. al., PNAS, 2010, 107 (32):14134-14139] on Ser-209.
Overexpression of eIF4E has been associated with tumoregenicity and studies
have indicated that eIF4E phosphorylation is oncogenic [Jinqiang Hou. et. al.,
Oncotarget, 2012, 3:118-131]. Therefore, Mnk1/2 inhibitors could be effective
therapeutic agents for the treatment of cancers driven by an overexpression of
phosphorylated eIF4E. In the current study we have carried out molecular
docking combined with molecular dynamics simulations to study the interac-
tion between ligand and Mnk1/2 kinase catalytic domains. Three dimensional
structures of both Mnk1 and Mnk2 were built using comparative modeling
methods. A series of Mnk kinase inhibitors were docked to the ensemble of
representative structures extracted from a clustering analysis of the MD simu-
lations. The predicted bound conformations were further studied in explicit sol-
vent by MD simulations. Our combined computation approach identified key
residues that are important for the protein - inhibitor interactions, provides
detailed understanding of the mechanism of these kinds of inhibitors and will
be useful for the rational design of Mnk inhibitors.
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Reperfusion injuries can cause severe damage in hypoxic tissue after the
blockage of oxygen supply has been relieved. The condition frequently occurs
after ischemic events or surgery and is caused by a combination of inflammation
and the generation of harmful reactive oxygen species (ROS). In an effort to gain
access to agents capable of combating the damaging effects of ROS, we devel-
oped compounds with dual properties capable of preventing the generation of
ROS and of absorbing ROS already formed. By combining two beneficial prop-
erties in a single molecule, we expected these compounds to bemore flexible and
effective than those that feature only one of the two activities. Based on the scaf-
folds of the natural products chalcone and caffeic acid phenethyl ester (CAPE),
we synthesized and tested a selection of compounds capable of inhibiting the
enzyme xanthine oxidase (XO), a major source of ROS production, and of
absorbing radicals. Assays employed in this study measured inhibitory potency
against XO activity, radical scavenging ability, and the capacity to increase
cell viability under oxidative stress. In addition, computational docking was per-
formed to elucidate XO/inhibitor interactions at the molecular level. Structure-
activity relationships were established that identified correlations between
molecular structure and the two bioactivities under investigation and that can
guide the future synthesis of materials with improved properties.
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Asmany as 30%of all proteins are phosphorylated. Protein kinases play a central
role in controlling cell proliferation, differentiation, cell cycle progression, and
angiogenesis - processes which frequently become dysregulated during carcino-
genic transformation. Many experimental therapeutics are developed using puri-
fied protein and may be less effective against targets that are post-translationally
modified in vivo. To test whether protein phosphorylation may decrease drug
binding and increase resistance, we examined 310 unique drug-bound protein
structures mapped from the DrugBank database to the Protein Data Bank. We
cross-referenced the sites with recorded phosphorylation sites found in the Phos-
phoSitePlus database. "Hits" are defined as target proteins that have phosphory-
lated residues within 12 A˚ of their drug binding sites. For these proteins,
phosphorylation could directly interfere with drug binding in vivo. The hits fellinto two classes. Class I hits are targets for which the drug compound competes
with natural substrate in the active site. The phosphorylation site is also in the
active site, and phosphorylation results in inactivation of the protein. One would
not expect a large reduction in drug efficacy for these proteins, as phosphorylation
simultaneously causes drug resistance and inactivates the protein target. ForClass
II hits, the drug compounds bind to allosteric sites outside the active site of the
target protein, and the documented phosphorylation either activates the target
or onlymoderately decreases its activity.Wehypothesize thatClass II compounds
aremore likely to encounter resistancewhen used as therapy, especially in cancer
where there are larger populations of aberrantly phosphorylated proteins.
1335-Pos Board B65
Effect of Natural Product Extracts on Lipoxygenase, Cyclooxygenase, and
Protein Tyrosine Phosphatase 1b
Magdalena M. Siodlak, Sharada T. Buddha.
Chemistry, Saint Xavier University, Chicago, IL, USA.
The purpose of this research project is to examine the inhibition of enzymes linked
to inflammation andassociateddiseasesbyplants traditionallyas anti-inflammatory
medicines: Tussilago farfara, Grindelia squarrosa, and Uritca dioica.
Arachidonic acid is metabolized in the body through two main metabolic path-
ways with the enzymes: cyclooxygenases (COX) and lipoxygenases (LOX).
Elevated levels of prostanoids and leukotrienes, products of the two respective
pathways, have been linked to inflammatory diseases. Finding a dual inhibitor
of COX and LOX is promising in preventing the inflammation and diseases that
are linked to the overproduction of both pathways while minimizing the side
effects associated with inhibition of individual pathways.
Furthermore, the enzyme protein tyrosine phosphatase 1b (PTP1b) is linked be-
tween inflammation and metabolic disease through the leptin receptor-associated
Janus Kinase (JAK). PTP1b is a negative regulator of insulin and leptin receptors
thus being explored as a possible therapeutic for type II diabetes and obesity.
Crude methanolic extracts of Tussilago farfara, Grindelia squarrosa, and
Urtica dioica were taken to approximate the plants’ components released in
the body upon consumption. The bioactivities of the standardized extracts
were then determined using enzymatic assay kits for COX I and II, LOX,
and PTP1b. T. farfara is the strongest LOX inhibitor at 60% inhibition of
15-LOX, followed by U. dioica and G. squarrosa at 45% and 39%, respec-
tively. Studies for COX I and II as well as PTP1b inhibition are ongoing,
and the results will be presented.
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The carbonic anhydrases (CA) are established as therapeutic targets [1]. There
are 12 catalytically active CA isozymes in human body. At least 30 CA sulfon-
amide inhibitors have been used as drugs to treat glaucoma, epileptic seizures,
altitude sickness, and as diuretics. However, most of them exhibit poor selec-
tivity towards target isozymes and result in various side effects.
In this work, a class of 4-substituted-2,3,5,6-tetrafluorobenzensulfonamides as
inhibitors of CA is reported. Crystal structures of CAII, CAXII and CAXIII
bound with the fluorinated compounds were solved and provided structural de-
tails of inhibitor binding. The binding affinity to carbonic anhydrases I, II, VII,
XII and XIII was measured by isothermal titration calorimetry and the fluores-
cent thermal shift assay, and inhibition was determined by stopped-flow CO2
hydration assay. The combined use of these methods has provided a detailed
picture of protein-ligand interactions. Experimentally obtained binding data
usually depends on various factors including temperature, pH, buffer, etc. In
this study, we present intrinsic parameters of binding that are independent of
experimental conditions. Structure-thermodynamics correlations were studied
using intrinsic parameters. All used biophysical methods have confirmed that
fluorinated sulfonamides bound stronger to CA than non-fluorinated, because
of the presence of electronegative substituents that decrease the pKa of sulfon-
amide group and this correlates with an increase in the CA inhibitory properties
[2]. A large group of fluorinated compounds possessed nanomolar affinity for
selected CAs and several of them were selective towards CAI.
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Proteins experience some conformational changes upon ligand bindings and their
effects on protein functions are displayed in variousways. Crystallographic data of
